日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network

原肌球蛋白受体激酶 (TRK) 融合肉瘤的诊断和治疗:世界肉瘤网络专家建议

Demetri, G D; Antonescu, C R; Bjerkehagen, B; Bovée, J V M G; Boye, K; Chacón, M; Dei Tos, A P; Desai, J; Fletcher, J A; Gelderblom, H; George, S; Gronchi, A; Haas, R L; Hindi, N; Hohenberger, P; Joensuu, H; Jones, R L; Judson, I; Kang, Y-K; Kawai, A; Lazar, A J; Le Cesne, A; Maestro, R; Maki, R G; Martín, J; Patel, S; Penault-Llorca, F; Premanand Raut, C; Rutkowski, P; Safwat, A; Sbaraglia, M; Schaefer, I-M; Shen, L; Serrano, C; Schöffski, P; Stacchiotti, S; Sundby Hall, K; Tap, W D; Thomas, D M; Trent, J; Valverde, C; van der Graaf, W T A; von Mehren, M; Wagner, A; Wardelmann, E; Naito, Y; Zalcberg, J; Blay, J-Y

Author Correction: Chemotherapy with radiotherapy influences time-to-development of radiation-induced sarcomas: a multicenter study

作者更正:放疗联合化疗影响放射性肉瘤的发生时间:一项多中心研究

Zhang, A Y; Judson, I; Benson, C; Wunder, J S; Ray-Coquard, I; Grimer, R J; Quek, R; Wong, E; Miah, A B; Ferguson, P C; Dufresne, A; Teh, J Y H; Stockler, M; Tattersall, M H N

Aggressive fibromatosis response to tamoxifen: lack of correlation between MRI and symptomatic response

侵袭性纤维瘤病对三苯氧胺的反应:MRI 与症状反应之间缺乏相关性

Libertini, M; Mitra, I; van der Graaf, W T A; Miah, A B; Judson, I; Jones, R L; Thomas, K; Moskovic, E; Szucs, Z; Benson, C; Messiou, C

Chemotherapy with radiotherapy influences time-to-development of radiation-induced sarcomas: a multicenter study

化疗联合放疗会影响放射性肉瘤的发生时间:一项多中心研究

Zhang, A Y; Judson, I; Benson, C; Wunder, J S; Ray-Coquard, I; Grimer, R J; Quek, R; Wong, E; Miah, A B; Ferguson, P C; Dufresne, A; Teh, J Y H; Stockler, M; Tattersall, M H N

Radiation induced angiosarcoma of the breast: outcomes from a retrospective case series

放射诱发乳腺血管肉瘤:回顾性病例系列研究结果

Cohen-Hallaleh, R B; Smith, H G; Smith, R C; Stamp, G F; Al-Muderis, O; Thway, K; Miah, A; Khabra, K; Judson, I; Jones, R; Benson, C; Hayes, A J

Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy

生长调节指数作为评估接受曲贝替定挽救治疗的晚期软组织肉瘤患者临床获益的指标

Penel, N; Demetri, G D; Blay, J Y; Cousin, S; Maki, R G; Chawla, S P; Judson, I; von Mehren, M; Schöffski, P; Verweij, J; Casali, P; Rodenhuis, S; Schütte, H J; Cassar, A; Gomez, J; Nieto, A; Zintl, P; Pontes, M J; Le Cesne, A

Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcoma: the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (STBSG) and French Sarcoma Group (FSG) study

欧洲癌症研究与治疗组织-软组织和骨肉瘤组 (STBSG) 和法国肉瘤组 (FSG) 的研究表明,体能状态是晚期软组织肉瘤患者早期死亡的最强风险因素。

Penel, N; Glabbeke, M V; Mathoulin-Pelissier, S; Judson, I; Sleijfer, S; Bui, B; Schoffski, P; Ouali, M; Marreaud, S; Brouste, V; Duhamel, A; Hohenberger, P; Blay, J-Y

Imaging of skeletal metastases in myxoid liposarcoma

黏液样脂肪肉瘤骨转移的影像学检查

Noble, J L; Moskovic, E; Fisher, C; Judson, I

Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?

新型分子靶向药物 I 期试验的临床获益:剂量重要吗?

Postel-Vinay, S; Arkenau, H-T; Olmos, D; Ang, J; Barriuso, J; Ashley, S; Banerji, U; De-Bono, J; Judson, I; Kaye, S

Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience

一项I期临床试验中接受治疗的患者的临床结果和预后因素:皇家马斯登医院的经验

Arkenau, H-T; Olmos, D; Ang, J E; de Bono, J; Judson, I; Kaye, S